New combo aims to fight recurrent brain tumors
Disease control
Recruiting now
This phase 2 trial tests a combination of two drugs—all-trans retinoic acid (ATRA) and retifanlimab—in 55 people with recurrent IDH-mutant glioma, a type of brain tumor. The goal is to see if the combo can shrink tumors or slow their growth. Participants take ATRA pills for 14 da…
Phase: PHASE2 • Sponsor: Stephen Bagley, MD, MSCE • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC